Macrosyn: Product Information (Page 4 of 4)
ANIMAL SAFETY
Cattle
Safety studies were conducted in feeder calves receiving a single subcutaneous dose of 25 mg/kg BW, or 3 weekly subcutaneous doses of 2.5, 7.5, or 12.5 mg/kg BW. In all groups, transient indications of pain after injection were seen, including head shaking and pawing at the ground. Injection site swelling, discoloration of the subcutaneous tissues at the injection site and corresponding histopathologic changes were seen in animals in all dosage groups. These lesions showed signs of resolving over time. No other drug-related lesions were observed macroscopically or microscopically.
An exploratory study was conducted in feeder calves receiving a single subcutaneous dose of 10, 12.5, or 15 mg/kg BW. Macroscopically, no lesions were observed. Microscopically, minimal to mild myocardial degeneration was seen in one of six calves administered 12.5 mg/kg BW and two of six calves administered 15 mg/kg BW.
A safety study was conducted in preruminant calves 13 to 27 days of age receiving 2.5 mg/kg BW or 7.5 mg/kg BW once subcutaneously. With the exception of minimal to mild injection site reactions, no drug-related clinical signs or other lesions were observed macroscopically or microscopically.
Swine
Safety studies were conducted in pigs receiving a single intramuscular dose of 25 mg/kg BW, or 3 weekly intramuscular doses of 2.5, 7.5, or 12.5 mg/kg BW. In all groups, transient indications of pain after injection were seen, including restlessness and excessive vocalization. Tremors occurred briefly in one animal receiving 7.5 mg/kg BW. Discoloration and edema of injection site tissues and corresponding histopathologic changes were seen in animals at all dosages and resolved over time. No other drug-related lesions were observed macroscopically or microscopically.
STORAGE CONDITIONS
Store at or below 25°C (77°F)
50 mL – Use within 28 days of first puncture and puncture a maximum of 17 times with a needle.
100 mL – Use within 28 days of first puncture and puncture a maximum of 17 times with a needle.
250 mL – Use within 28 days of first puncture and puncture a maximum of 29 times with a needle or 5 times with a dosage delivery device. If using a needle or draw-off spike larger than 4 gauge, discard any remaining product immediately after use.
500 mL – Use within 28 days of first puncture and puncture a maximum of 29 times with a needle or 5 times with a dosage delivery device. If using a needle or draw-off spike larger than 4 gauge, discard any remaining product immediately after use.
HOW SUPPLIED
Macrosyn Injectable Solution is available in the following package sizes: 50 mL, 100 mL, 250 mL and 500 mL vial.
MacrosynTM is a Trademark of Bimeda, Inc.
Manufactured for: Bimeda, Inc. Le Sueur, MN 56058 www.bimeda.com | N.A. Corp. Address: Bimeda, Inc., One Tower Lane, Oakbrook Terrace, IL 60181 |
Approved by FDA under ANADA # 200-657
To report suspected adverse drug events, for technical assistance, or to obtain a copy of the Safety Data Sheet (SDA), contact Bimeda, Inc. at 1-888-524-6332. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov/reportanimalae.
250 mL
MACROSYN tulathromycin injection, solution | |||||||||||||||||||||||||
| |||||||||||||||||||||||||
| |||||||||||||||||||||||||
| |||||||||||||||||||||||||
|
Labeler — Bimeda, Inc. (060492923) |
Establishment | |||
Name | Address | ID/FEI | Operations |
Bimeda- MTC | 256232216 | manufacture |
Establishment | |||
Name | Address | ID/FEI | Operations |
Wisdom Parmaceutical Co., Ltd. | 527609114 | api manufacture |
Revised: 02/2021 Bimeda, Inc.
VetLabel.com provides trustworthy package insert and label information about marketed drugs as submitted by manufacturers to the U.S. Food and Drug Administration. Package information is not reviewed or updated separately by VetLabel.com. Every individual animal healthcare product label entry contains a unique identifier which can be used to secure further details directly from the U.S. National Institutes of Health and/or the FDA.